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for HIV infection and 972 womenwithout HIV infection recruited from 6 national metropolitan locations.
The clinical database information collected for each HIV-positive individual included CD4 cell counts,
viral load, and antiviral treatment to evaluate HIV prognosis and related conditions in women.
Objective: To provide a baseline for ﬂuconazole treatment prospects in women who test positive for HIV
infection. As part of the ongoing Women’s Interagency HIV Study project, we investigated the
ﬂuconazole susceptibility of Candida spp. isolated from women with HIV in comparison to volunteer
women without HIV. The implication of antifungal treatment on ﬂuconazole susceptibility was evaluated
by reviewing antifungal medication use for the past 2 years in each participant. In addition, genotyping
of Candida spp. at oral and vaginal sites was monitored for 4 months in 9 patients.
Methods: In a cohort of 59 women with HIV and 24 women without HIV, colonization by Candida
albicans and non-albicans species of the oral and vaginal sites was ﬁrst determined. Fluconazole
susceptibility was surveyed in vitro according to Clinical and Laboratory Standards Institute protocol.
Antifungal drug treatment history was investigated for each patient to correspond with ﬂuconazole
susceptibility. Finally, series of isolates from several patients were followed for resistance and
susceptibility. Their lineage was veriﬁed by genotyping multilocus sequence typing (MLST).
Results: A total of 280 Candida strains were recovered from oral and vaginal swabs of women with and
without HIV infection. We found that patients with HIV were colonized with Candida spp. more
frequently than women without HIV. The percent of isolates that were susceptibility dose dependent
or resistant to ﬂuconazole was higher in Candida glabrata compared with C. albicans isolates, but higher
for C. albicans than other published data. Resistance was noted to be more common in vaginal sites.
Fluconazole resistance in either species was not associated with relative CD4 cell counts or viral load.
However an association with systemic application of ﬂuconazole and resistance was noted.
Conclusions: Systemic antifungal therapy, including a vaginal topical regimen in women with HIV
infection correlated with reduced ﬂuconazole susceptibility of oral and vaginal isolates. Genotype
proﬁling has disclosed that a majority of isolates from the same individual are clustered together,
suggesting the likelihood of an original strain with some microevolution. We observed a change from a
susceptibility dose dependent to a resistant phenotype of isolates in 2 women with HIV infection, even
though no treatments were received during the 4-month study and the prior 2 years.
& 2014. The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Candida species are a major source of fungal infections in
patients with HIV/AIDS. The colonization by this organism in the
oral mucosa can result in the development of oropharyngeal
candidiasis (OPV) in 90% and esophageal candidiasis (EC) at early
and late stages of an HIV infection.1 Vulvovaginal candidiasis (VVC)
is more common in women infected with HIV, but is clinically
similar to that experienced in HIV-negative women.2 For both
OPV/EC and VVC, ongoing concerns are non-albicans Candida
species and their drug resistance. The current treatment for
candidiasis heavily relies on triazoles such as ﬂuconazole, itraco-
nazole, and now posaconazole even though patient responses to
these antifungal drugs tend to be slow with a high risk of
reinfection.3 The clinical relapse of candidiasis is obviously
dependent on the degree of immunosuppression in individuals
infected with HIV and the development of drug resistance.1 About
5% of patients with HIV/AIDS develop a ﬂuconazole-refractory
mucosal candidiasis as described in an 800-case cohort study.3
Treatment failures can occur due to antifungal drug toxicity, but
more importantly, drug resistance development.4 Primary resist-
ance to ﬂuconazole, for example, can result in cross-resistance to
other unused triazoles. Resistance to imidazoles such as clotrima-
zole and ketoconazole has been reported.1 Thus, a concern in
management of candidiasis in this immunocompromised group is
the selection of resistant non-albicans Candida spp. following
prophylactic treatment with azoles, which has been conﬁrmed in
a high risk population.4 In fact, the high mortality rate of invasive,
bloodborne candidiasis (15%–49%) has decreased little over the
past 2 decades despite triazole therapeutics.4,5 As expected,
patients colonized with ﬂuconazole-resistant strains of Candida
spp also have a higher prevalence of reinfection than those
colonized with more susceptible strains.6 The existing paradigm
is that patients treated previously with ﬂuconazole should not be
treated with the same drug during a reinfection. However the
short- and long-terms effects on Candida species colonization
following the treatment of OPV/EC and VVC candidiasis in patients
with HIV/AIDS remain unknown. How the use of speciﬁc triazoles
at speciﬁc doses and duration affect Candida colonization at
different anatomic locations are not clearly determined, especially
after treatment is discontinued. In our study we surveyed ﬂuco-
nazole susceptibility in 280 isolates from our previous study on the
probiotic effects on Candida spp. colonization in patients with HIV/
AIDS.7 The isolates were obtained from oral and vaginal swabs of
59 women with HIV infection and 24 HIV-negative female volun-
teers with comparable socioeconomic status. The drug-use history
for each individual was followed for 2 years before the current
observations. The objective of our study was to provide a baseline
for ﬂuconazole susceptibility/resistance in HIV-positive women.
In addition to the susceptibility testing of isolates, we also
chose 30 C. albicans strains from oral and vaginal cultures of
9 patients to analyze their genotype by multilocus sequence typing
(MLST). Combined with ﬂuconazole susceptibilities of both oral
and vaginal isolates, MLST provides assurances that persistence of
isolates with susceptibilities was not due to replacement by new
isolates.Materials and Methods
Study population, clinical data, and infection treatment history
As described in previous studies,7,10 the patient population
included 59 patients with HIV infection and 24 HIV-negative
volunteers recruited from the Women's Interagency HIV Study
(WIHS) cohort.8,9 The WIHS was established in 1993 to study thenatural history of HIV disease among women in the United States,
and currently has enrolled 2,895 HIV-infected women and 972
HIV-uninfected women recruited from 6 national metropolitan
locations. The local institutional review board at each site
approved the study protocol and all participants gave written
informed consent.
The viral loads and CD4 lymphocyte counts for each patient
were determined by standard methods and documented in a
previous study.7 No antibiotics were used by the patients during
the study and participants had a short period of probiotic treat-
ment as described previously.10 Because this study focused on the
implications of antifungal drug treatment on the development of
resistance, a 2-year retrospective antifungal drug history was
reviewed in each patient.
Strains collection and growth medium
Samples were collected as previously described at 0, 30, 60, 74,
and 129 days following a diagnosis of HIV infection.7,10 All isolates
were identiﬁed at the species level, and semiquantitation of isolate
levels (scale ¼ 0–4) was done as previously described.7 C. albicans
SC5314 was also included in MIC and genotyping studies as a
reference strain. Yeast extract peptone dextrose (YPD) broth
(2% yeast extract, 1% peptone, and 2% glucose) or YPD agar was
used to propagate strains from –801C stock cultures.
Antifungal activity assays
Roswell Park Memorial Institute 1640 medium (Sigma, St Louis,
Missouri) buffered to pH 7.0 with 0.165M 3-(N-morpholino)
propanesulfonic acid buffer was used for determinations of iso-
lates ﬂuconazole susceptibility. MIC assays were performed using
the standardized broth microdilution protocol (M27-A) of the
Clinical and Laboratory Standards Institute (version 2008).11
Brieﬂy, ﬂuconazole was diluted in the Roswell Park Memorial
Institute 1640 medium described above in 96-well microtitre
plates to ﬁnal concentrations of 128 μg/mL to 0.125 μg/mL
ﬂuconazole. Isolates were each added to achieve a ﬁnal concen-
tration of 103 cfu/100 mL. The microtitre plates were incubated at
351C for 48 hours in a humid chamber. MIC50 values were
determined using a plate reader at optical density ¼ 600 nm
(Spectra Max 190, Molecular Devices, LLC., Sunnyvale, Californian).
Fluconazole breakpoints for each isolate were assigned as
susceptible (S), MIC r8 mg/mL; susceptible dose dependent
(SDD), MIC ¼ 16 to 32 mg/mL; or resistant (R), MIC Z64 mg/mL
using the M27-A protocol for all isolates. MIC assays in triplicate
always included C. albicans SC5314 as a reference strain.
Genotyping assays
DNA from 29 C. albicans isolates of 9 HIV-positive patients and
SC5314 was extracted from overnight cultures grown in 5 mL YPD
broth. The cells were broken with glass beads and treated with
phenol-chloroform (1:1). Genomic DNA was collected, dissolved in
tris and EDTA buffer, and concentrations were determined using
the Nana drop Bioanalyzer 2100 (Agilent Technologies Inc., Colum-
bia, Maryland).
Polymerase chain reaction (PCR) assays were done in a 50 mL
volume of primers and a DNA polymerase mixture containing 200
ng DNA from each isolate. The PCR reaction mix was incubated for
2 minutes at 941C, followed by 40 cycles of denaturation at 941C
for 1 minute, annealing at 561C for 30 seconds, and elongation at
721C for 1 minute, and an additional 10 minutes at 721C. DNA
fragments in the range of 450 to 550 bp were ampliﬁed using Vent
DNA polymerase (New England Biolabs, Lpswich, Massachusetts)
with 6 sets of primers that have been described elsewhere.12,13
Table II
Oral and vaginal isolates with reduced ﬂuconazole susceptibility (Candida albicans
and Candida glabrata), by HIV status.
Number of isolates tested (% at MIC)
MIC50 (μg/mL) HIVþ HIV–
Vaginal Oral Vaginal Oral
0.125-8 49 (68.1) 106 (76.8) 13 (100) 33 (86.8)
16-32 13 (18.1) 15 (10.9)
Z64 10 (13.8) 17 (12.3) 5 (13.2)
Total 72 138 13 38
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highly conserved enzymes in L-aspartate biosynthesis; PMI1, syn-
thesis of GDP-mannose; ADP1; PDR-subfamily ABC transporter;
ALA1, alanine-tRNA ligase; and RPN2, 26S proteasome regulatory
subunit. Amplicons were detected in 1% agarose gels and puriﬁed
using the PCR puriﬁcation kit (Qiagen, Gaithersburg, Maryland).
One-strand DNA sequence data for each sample were obtained by
Sanger DNA sequencing provided by Genewiz Inc., Germantown,
Maryland (www.genewiz.com).
Statistical analysis
SAS 9.2 (SAS Institute Inc, Cary, North Carolina) was used for
statistical analysis in this study. The similarity among strains from
MLST study was analyzed by Cluster X software (The European
Bioinformatics Institute). The DNA sequence data of each gene
were aligned and polymorphic loci were determined. The numbers
of variable loci were scored for each pair of strains. Diversity of
strain distribution is shown in a dendrogram created by Mega
5.1 software (Arizona State University).14Results
Colonization by Candida spp. is inﬂuenced by HIV status
The majority of the patient cohort was African American
women who had a higher viral load than the general WIHS cohort
(log mean value ¼ 6.12 vs 5.42).7 During a 4-month survey, 18.6%
of patients testing positive for HIV infection (11 out of 59) and
33.3% of patients testing negative for HIV infection (8 out of 24)
had negative yeast cultures. Whereas colonization was observed in
both patients with and without HIV infection, the overall carriage
rate of Candida spp. in women testing positive for HIV infection
was signiﬁcantly higher than HIV-negative women from both the
oral and vaginal mucosa (83.0% [n ¼ 48 out of 59] vs 66.7% [n ¼ 16
out of 24], respectively; P r 0.05).7 Also, 28.8% of HIV patients
(n ¼ 17 out of 59) were colonized with non-albicans Candida spp.
compared with 16.7% in the HIV-negative group. Most of the non-
albicans Candida spp. strains (19.11%) were isolates from the vagina
of women with HIV infection.
Fluconazole susceptibility proﬁles of isolates
C. albicans and C. glabrata accounted for 261 of the 280 isolates.
MIC values for ﬂuconazole of 227 C. albicans and 34 C. glabrata
isolates were determined (Table I). We chose MIC50 determina-
tions instead of using MIC90 because of an obvious trailing effect,
deﬁned as a persistent growth of Candida spp. with drug concen-
trations above the MIC50 after 48 hours of incubation. This
observation was not unexpected because most of the isolates were
from patients with HIV infection. The overall frequencies at each
breakpoint for ﬂuconazole of C. albicans were susceptible, 81.9%; R,
10.6%; and SDD, 7.5%. In contrast to C. albicans, C. glabrata isolatesTable I
Fluconazole susceptibility proﬁles of Candida spp. isolates from patients with and
without HIV, in oral or vaginal candidiasis.
Number of isolates tested (% for each MIC)
MIC50 (μg/mL) C. albicans C. glabrata C. parapsilosis/C. tropicalis/C. spp.
0.125-8 186 (81.9) 15 (44.1) 12 (63.2)
16-32 17 (7.5) 11 (32.4) 0
Z64 24 (10.6) 8 (23.5) 7 (36.8)
Total 227 34 19were less susceptible to ﬂuconazole (frequency of 44.1%) and had
increased resistance (frequency of 23.5%), whereas SDD was 32.4%.
The MIC proﬁles of strains from each patient remained similar for
the entire course of this study in patients positive for HIV infection
(n ¼ 39) compared with those patients for whom MIC values
changed (n ¼ 11). In the latter group, the MICs of ﬂuconazole from
isolates of 2 patients with HIV (patients 5 and 7) increased from
SDD to R.
Isolates of Candida spp. from the group of women testing positive for
HIV are less susceptible to ﬂuconazole
Resistance to ﬂuconazole of our isolates described in Table I
was higher than most other published data (r 3% for C. albi-
cans).15 Vaginal isolates of C. albicans and C. glabrata from the
group of women testing positive for HIV were more resistant to
ﬂuconazole compared with women without HIV. We found that in
comparison of 100% susceptibility of the group of women without
HIV, only 68.1% of vaginal isolates recovered from the group of
women with HIV were susceptible to ﬂuconazole for both species
(Figure 1). At same time, 18.1% were SDD and 13.8% were resistant
to ﬂuconazole among vaginal isolates. On the other hand, the
percentage of resistance to ﬂuconazole in oral isolates was similar
in both patients with HIV infection and HIV-negative volunteers
(12.3% vs 13.2%) in Table II.
The MIC proﬁles of isolates are not related to CD4 cell counts
Untreated HIV infection leads to a progressive reduction in the
number of T cells that express CD4. Patients testing positive for
HIV infection with CD4 counts 4500 cells/mm3 are not at risk for
opportunistic infections; however, when that number drops to 200
to 500 cells/mm3, candidiasis occurs. In our study the isolates from
patients with CD4 counts above 500 cells/mm3 were mostly
susceptible to ﬂuconazole. Exceptions were 4 patients, 3 of whom
tested positive for HIV infection, and 1 who tested negative for HIV
infection. We then compared MIC proﬁles of each resistant isolate
to patient CD4 counts (cells/mm3) and viral load (Table III). We
found that ﬂuconazole resistance in C. glabrata isolates occurred
regardless of the relative CD4 cell counts or viral load (Table III).
All resistant C. albicans strains were from patients with CD4 counts
r700 mm3/mL except 1 case, and 5 out of 9 patients with CD4
counts r500 mm3/mL.
To better explain the high resistance to ﬂuconazole in this
group of patients with HIV infection, we traced the antifungal drug
treatment for the previous 2 years for each participant because
only 1 patient with HIV received ﬂuconazole treatment during our
4-month surveillance study. As shown in Table III, 6 of 12 patients
testing positive for HIV infection with high MICs (SDD or R) had
received antifungal drugs during the past 2 years. Yet the fre-
quency of antifungal drug use in patients with HIV infection was
32% during the past 2 years (19 out of 59) (Table IV). These
Table III
Fluconazole susceptibility of dose dependent/resistant isolates and the relationship
to CD4 cell counts and viral load among HIV-positive patients.
Candida
spp.
MIC50 (μg/mL) CD4
(cells/mm3)
Viral load
(copies)
Antifungals
used
V-strain O-strain
C. albicans 32 64 111 1,160,000 -
C. albicans 64 32 160 1,330,000 -
C. albicans 64 64 208 2,950 FCZ
C. tropicalis 64 64 290 80 FCZ
C. albicans 64 64 428 48 -
C. albicans 16 - 535 76 FCZ
C. albicans 64 - 602 48 -
C. albicans 64 64 697 48 FCZ
C. albicans 64 - 1080 48 -
C. glabrata 32 16 890 108 FCZ þ MCZ
C. glabrata 16 16 1,091 48 -
C. glabrata 64 64 1,225 48 FCZ
FCZ ¼ ﬂuconazole prescribed at least once in past 2 years; MCZ ¼ miconazole
typical used at least once in past 2 years; O-strain ¼ oral isolates of Candida spp;
V-strain ¼ vaginal isolates of Candida spp.
Table IV
MICs of oral and vaginal isolates with a patient history of antifungal use during the
past 2 years.
HIVþ (n ¼ 19/59) HIV– (n ¼ 9/24)
Vaginal Oral
Candida
spp. (V/O)
Drug
used*
Vaginal Oral
Candida
spp. (V/O)
Drug
used†
16.0 - alb /- FCZ 64.0 0.125 gla /alb MCZ
- - - / - FCZ 0.25 - par /- FCZ
1.0 0.25 alb/alb FCZ - 0.125 - / alb MCZ
- 4.0 -/alb FCZ 8.0 - kru /- MCZ
64.0 64.0 trp/trp FCZ - 0.125 - / alb MCZ
64.0 64.0 alb/alb FCZ - 1.0 - / alb MCZ
- 2.0 - / gla FCZ 0.5 0.5 alb/alb MCZ
- 0.5 - / gla FCZ - - - / - MCZ
2.0 2.0 alb/alb FCZþMCZ - 64.0 - /alb MCZ
4.0 - gla / - FCZ
0.5 4.0 fam/alb FCZþMCZ
64.0 64.0 par/alb FCZ
0.5 - alb / - MCZ
- 4.0 - / alb FCZ
1.0 2.0 alb/alb FCZ
0.25 0.125 alb/alb FCZþMCZ
64.0 64.0 gla/gla FCZ
32.0 16.0 gla/alb FCZþMCZ
0.25 0.25 alb/alb FCZ
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with miconazole. Although a similar percentage of antifungal
drugs had been used in HIV-negative volunteers (37.5%; n ¼
9 out of 24), the treatment modes were mostly restricted to
miconazole topical use (Table IV). Only a single volunteer without
HIV received ﬂuconazole.
MLST characterization of oral and vaginal isolates
We typed 30 isolates of C. albicans from 9 of HIV infected
patients with oral or vaginal candidiasis by MLST.12–14,16 The
objective of these experiments was to look for persistence and
changes in susceptibility to ﬂuconazole at times during the full
course of this study and also determine if oral and vaginal isolates
from the same patient were genotypically similar. PCR ampliﬁca-
tion of 6 housekeeping genes was used to determine relatedness
among isolates. We found 49 polymorphic loci among the 30
strains by MLST (Figure 1). The majority of these isolates are
members of clade I of C. albicans using a threshold of 0.002 and
C. albicans SC5314 as a reference strain. Isolates from Patients 2, 4,
5, 8, and 9 are likely the same strain with some microevolution.
From Patient 7, the 30-day isolate clearly represents a different
strain from a different clade. Patient 1 isolates appeared to be
divergent and represent different strains.
Vaginal isolates were more divergent than oral isolates, sug-
gesting that, in general, a separate microevolution between the
oral and vaginal niches occurred with frequent recolonization from
1 niche to the other.
Persistent ﬂuconazole resistance and/or SDD phenotypes were
noted in Patients 1, 5, and 7. Of these 3 patients, R or SDD was
observed in oral (Patient 1) or vaginal (Patient 7) isolates only. Patient
5 oral isolates initially were SDD (MD) but by 120 days became
resistant (MR) although ﬂuconazole therapy was not used during this
study. In the same patient, cluster-similar isolates from the vagina
were SDD (MD) (Figure 1). The vaginal isolate from Patient 7 also
changed from SDD to R during the 4-month surveillance. All other
isolates from the remaining patients were susceptible to ﬂuconazole
throughout the course of this study (Figure 1).- ¼ no Candida spp. was isolated during 4 months surveillance; alb ¼ Candida
albicans; fam ¼ Candida famata; gla ¼ Candida glabrata; kru ¼ Candida krusei;
trp ¼ Candida tropicalis; FCZ ¼ ﬂuconazole; MCZ ¼ miconazole.
n Nineteen HIV-positive patients were prescribed with FCZ at least once during
past 2 years.
† Nine HIV-negative individuals were prescribed once or multiple times MCZ
for vaginal topical use during past 2 years.Discussion
In general, reduced susceptibility to ﬂuconazole was prevalent in
this patient cohort. We found that resistance to ﬂuconazole among
isolates was 10.6% and 23.5% for C. albicans and C. glabrata,Meanwhile, SDD to ﬂuconazole was 7.5% and 32.4% for C. albicans
and C. glabrata, respectively. The latter is interpreted as those strains
with MICs of 16 to 32 mg/mL to ﬂuconazole. The clinical implication of
SDD with high MICs in vitro is to achieve maximal ﬂuconazole levels
in blood and tissue to inhibit fungal growth.17–19 With higher
resistance and SDD occurred among C. glabrata isolates, C. albicans
isolates were more susceptible (81.9%) to ﬂuconazole than C. glabrata
(44.1%). In patients who tested positive for HIV, the less susceptible
strains were especially isolated from vaginal cultures.
No clear correlation between MIC proﬁles and viral load or CD4
counts has been found in patients testing positive for HIV infection.
Most isolates were susceptible to ﬂuconazole at CD4 counts 4500
cells/mm3. However, except for 1 isolate, all resistant C. albicans
strains were isolated from patients with CD4 counts r700 cells/
mm3.7 The higher amount of resistance in the HIV-positive group may
imply an association with inappropriate therapy, deﬁned as delay in
treatment, wrong dosage, or treatment of a patient with a resistant
isolate.17 In fact, a retrospective review of patient history 2 years
before this study showed that about 32% of patients positive for HIV
infection had oral ﬂuconazole treatment alone or with antifungal
topical agents. In contrast to a higher frequency of ﬂuconazole use in
the group of patients testing positive for HIV, the percentage of
ﬂuconazole treatment was only 4% in individuals without HIV,
although some of these individuals received topical miconazole
treatment. Intriguingly 7 patients with resistant isolates were colon-
ized from the ﬁrst day of surveillance and, possibly, the isolates were
transmitted from vaginal to oral sites or oppositely from oral to a
vaginal site. The implication is that optimal use of ﬂuconazole may
need adherence to established methods of treatment.
From 30 isolates of 9 patients, ﬂuconazole susceptibility proﬁles
from 6 of the 9 patients appeared to be stable during the 4-month
surveillance. All isolates from those 6 patients remained suscep-
tible to ﬂuconazole. Resistance and SDD were noted in 3 of the
9 patient isolates, with progression from SDD to R in the oral
isolates. For patients in whom both oral and vaginal isolates were
5+OD0MD
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5+OD120MR
5+VD30MD
5+VD74MD
5+VD120MD
9+VD0MS
9+VD30MS
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4-OD0MS
4-OD90MS
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Figure 1. The relatedness of 30 clinical isolates and 1 standard strain (WT) of Candida albicans based on the multilocus sequence typing genotyping. This unweighted pair-group
method with arithmetic averages dendrogram was generated with Clustalx 1.81 and Mega 5.1. 1-9 ¼ Patients 1 to 9; þ/- ¼ HIV positive/negative; D# ¼ isolation day; MD ¼
ﬂuconazole dose-dependent susceptible; MR ¼ ﬂuconazole resistant; MS ¼ ﬂuconazole susceptible; V/O ¼ vaginal isolates or oral isolates.
L. Zhang et al. / Current Therapeutic Research 76 (2014) 84–8988sampled, isolates were apparently of the same genotype and had
similar susceptibility proﬁles except for the progression from SDD
to R in Patient 5. Cross-transmission among both sites could be an
explanation of isolate similarity.
The change in ﬂuconazole susceptibility of an isolate from SDD to
R in Patient 5 is intriguing in light of the lack of ﬂuconazole treatment
during the 4-month surveillance. C. albicans is known to undergo a
loss of heterozygosity that can be associated with conversion to lower
ﬂuconazole susceptibility.15 Loss of heterozygosity can be reversed by
a number of processes, including gene conversion. We suggest that a
gain-of-function mutation has occurred in this isolate.13 Mrr1p and
Tac1p, regulators of azole efﬂux pumps, are 2 candidates, both of
which could contribute to the decreased susceptibility that only was
recognized during our routine susceptibility assays.Vaginal isolates of Candida spp. in patients with HIV infection
displayed an increase in drug resistance. Antifungal over-the-
counter treatments may have contributed to the increased resist-
ance. The risk of transfer of resistant isolates Candida spp. from a
vaginal to an oral site (or its reverse) in patients with HIV infection
will require additional study. Taken together, the higher frequency
of resistance of C. albicans and non-albicans Candida spp. in the
group of patients with HIV is challenging therapeutically and
should encourage the development of new antifungal drugs,
alterations in drug dosing, or encourage routine susceptibility
testing in patients with candidiasis.16–18 Colonization and drug
susceptibility studies of these patients provided a good baseline
for ongoing projects, especially in regard to treatment intervention
or to monitor reinfection in patients.
L. Zhang et al. / Current Therapeutic Research 76 (2014) 84–89 89Conclusions
Vaginal isolates of Candida spp. in patients testing positive for
HIV infection displayed an increase in drug resistance. Thirty-two
percent of womenwith HIV infection had received oral ﬂuconazole
and antifungal over-the-counter treatments that may have con-
tributed to the increased resistance seen in this group of patients.
The results also suggested that the transfer of resistant isolates of
Candida spp. from a vaginal to an oral site may have occurred.Acknowledgments
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